Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
The Role of Membrane Lipids in Placentation and in the Etiology of Congenital Heart Defects
EF 2024-25
Résumé
Congenital Heart Defects (CHD) are the most common birth defect affecting 1% of newborns. Despite extensive research efforts, only 15-20% of CHD cases have an identified genetic cause. However, recent evidence using mouse models has revealed placental defects as a sole cause of CHD, this finding has been corroborated in humans using correlative studies. Placenta-Heart Axis (PHA) genes are those whose proper functioning in the placenta is required for normal heart development. The placenta is a transient organ formed during pregnancy to support the developing fetus. Its most recognized role is as the site of nutrient and waste exchange between mother and fetus. A key component of successful placentation is the formation of a specialized cell type, called the syncytiotrophoblast (SynT) cells, this cell type is formed through the fusion of progenitor cells. Defective SynT formation has been specifically identified as causative of CHD. In my project, I will use an in vitro mouse placenta stem cell line to study the role of proposed PHA genes in SynT formation. This in vitro method was chosen for its ease of genetic manipulation and the possibility for in depth molecular analysis of gene expression. The objectives of this project are to identify novel PHA genes by detailed database screening and data integration, to generate placenta stem cell lines deficient in candidate PHA genes and assess any disruptions in SynT formation, and finally to gain a better understanding of the critical time points and molecular steps of the cell-cell fusion process using a known fusion inhibitor. The findings from this project will increase our understanding of the developmental origins of CHD, uncover potential biomarkers of CHD in pregnancy and present novel drug targets for CHD treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537999
Name
Apantaku Ifeoluwa
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Membrane Lipids in Placentation and in the Etiology of Congenital Heart Defects
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Congenital Heart Defects; Crispr Gene Editing; Development; Embryogenesis; Heart; Interhemal Barrier; Membrane; Placenta; Syncytiotrophoblast; Trophoblast Stem Cells
Abstract
Congenital Heart Defects (CHD) are the most common birth defect affecting 1% of newborns. Despite extensive research efforts, only 15-20% of CHD cases have an identified genetic cause. However, recent evidence using mouse models has revealed placental defects as a sole cause of CHD, this finding has been corroborated in humans using correlative studies. Placenta-Heart Axis (PHA) genes are those whose proper functioning in the placenta is required for normal heart development. The placenta is a transient organ formed during pregnancy to support the developing fetus. Its most recognized role is as the site of nutrient and waste exchange between mother and fetus. A key component of successful placentation is the formation of a specialized cell type, called the syncytiotrophoblast (SynT) cells, this cell type is formed through the fusion of progenitor cells. Defective SynT formation has been specifically identified as causative of CHD. In my project, I will use an in vitro mouse placenta stem cell line to study the role of proposed PHA genes in SynT formation. This in vitro method was chosen for its ease of genetic manipulation and the possibility for in depth molecular analysis of gene expression. The objectives of this project are to identify novel PHA genes by detailed database screening and data integration, to generate placenta stem cell lines deficient in candidate PHA genes and assess any disruptions in SynT formation, and finally to gain a better understanding of the critical time points and molecular steps of the cell-cell fusion process using a known fusion inhibitor. The findings from this project will increase our understanding of the developmental origins of CHD, uncover potential biomarkers of CHD in pregnancy and present novel drug targets for CHD treatment.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Apantaku, Ifeoluwa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~